Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose
Frontiers in Psychiatry · 06.07.2026 · 17
DOI: 10.3389/fpsyt.2026.1863924 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 06.07.2026. Verfasst von Kareem Woods und 3 weiteren Autor:innen. Beteiligte Einrichtung: United States Department of Veterans Affairs, VA Portland Health Care System, Veterans Health Administration, Portland, OR, United States. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long-acting injectable buprenorphine (LAIB) has generated enthusiasm as a potential tapering strategy for patients seeking discontinuation from buprenorphine therapy. The rationale is pharmacokinetic: gradual decline in plasma concentrations over months may blunt or prevent withdrawal. Yet protocols, clinical risks, and the characteristics of delayed withdrawal during LAIB tapers are poorly described. Case We report a 45-year-old man who developed somatic withdrawal symptoms four months after receiving a single 200 mg dose of LAIB (Sublocade) as a tapering tool following years of stability on sublingual buprenorphine. Administration of 12.5 mg naltrexone precipitated a clinically significant worsening of withdrawal, supporting ongoing μ-opioid receptor agonism at month four. Symptoms were attenuated with transdermal buprenorphine (20 mcg/hr) as rescue therapy.
Interpretation
This case underscores under-recognized risks of delayed withdrawal during LAIB-facilitated discontinuation and illustrates how loss of kappa opioid receptor (KOR) antagonism may contribute to the emergence or exacerbation of mood-like symptoms (e.g., anhedonia, dysphoria) that can be misattributed to primary psychiatric disorders rather than atypical withdrawal.
Implications
Comprehensive tapering protocols, extended monitoring (6–12 months), reinforcement of recovery capital (defined as the sum of internal and external resources that support sustained recovery), and explicit informed consent about delayed withdrawal are essential when considering LAIB to discontinue buprenorphine. Clinicians should anticipate the need for bridging strategies, including symptomatic agents (such as clonidine or gabapentin), or buprenorphine rescue (temporary or return to maintenance)—and weigh formulation differences (Sublocade vs Brixadi) when planning stepwise tapers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- United States Department of Veterans Affairs, VA Portland Health Care System, Veterans Health Administration, Portland, OR, United States.
- Oregon Health & Science University, Portland, OR, United States.
- VA Portland Health Care System, Portland, OR, United States.
Zitieren
APA
Woods, K., Graham, S., Dobscha, S., & Blazes, C. (2026). Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1863924
Vancouver
Woods K, Graham S, Dobscha S, Blazes C. Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1863924
BibTeX
@article{Woods2026,
author = {Woods, Kareem and Graham, Sophia and Dobscha, Steven and Blazes, Christopher},
title = {Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1863924}
}
EUVIMED